Fellowship · New Brunswick, NJ
Sponsored by Rutgers Health
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
The Lancet. Infectious diseases · 2023 · 267 citations · Keith Kaye
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
The Lancet. Microbe · 2023 · 265 citations · Keith Kaye
Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update.
Infection control and hospital epidemiology · 2023 · 204 citations · Keith Kaye
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
The Lancet. Infectious diseases · 2021 · 400 citations · Keith Kaye
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024 · 93 citations · Keith Kaye
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.
The Lancet. Infectious diseases · 2025 · 62 citations · Keith Kaye, Anjali Majumdar
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
NEJM evidence · 2023 · 128 citations · Keith Kaye
Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement.
JAMA network open · 2024 · 74 citations · Ahmed Azim